View this expert discussion, along with downloadable slides, for valuable updates and expert perspectives on exciting new data on estrogen receptor (ER)-positive breast cancer from the 2019 Breast Cancer Meeting in San Antonio.
Dec 19, 2019
Dec 19, 2020
- Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France
- Wolfgang Janni, MD, PhD, University of Ulm, Ulm, Germany
- Debu Tripathy, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Abstract GS2-06: Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study
Abstract P2-11-01: Immune response following neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 luminal B early breast cancer: A correlative analysis of the SOLTI-1402 CORALLEEN phase 2 randomized trial
Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of palbociclib (PAL) in combination with endocrine therapy (ET) versus capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)
Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice
Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer
Abstract P1-19-09: Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)
Abstract P4-10-04: Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study
Debu Tripathy, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Fabrice André, MD, PhDGustave Roussy
Wolfgang Janni, MD, PhDUniversity of Ulm
This educational activity is designed for hematology/oncology specialists, obstetricians & gynecologists, and surgeons based outside of the United States who are involved in the management of patients with breast cancer.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the:
- Efficacy and safety findings from recent clinical studies investigating novel treatment strategies for ER+ breast cancer across the disease continuum
- Have greater competence related to:
- Application of optimal strategies to incorporate emerging treatment strategies into clinical decision making
- Demonstrate greater confidence in their ability to:
- Apply optimal strategies that incorporate emerging treatment therapies in order to improve patient outcomes
This educational activity is supported by Novartis Oncology.
Independent Medical Education (IME)
This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME, a Medscape Oncology Company.
Disclosure of Relevant Financial Relationships
prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr André has disclosed the following relevant financial relationships:
- Received grants for clinical research from: AstraZeneca; Daiichi; Eli Lilly; Novartis; Pfizer; Roche
Dr Janni has disclosed the following relevant financial relationships:
- Served as an advisor or consultant for: Novartis
- Received grants for clinical research from: Novartis
Dr Tripathy has disclosed the following relevant financial relationship:
- Served as an advisor or consultant for: Novartis; Pfizer
- Served as a speaker or a member of a speakers bureau for: Genomic Health
- Received grants for clinical research from: Novartis
The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.
Esther Nyarko, PharmD
Associate Director, Accreditation and Compliance
Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.